Structure Therapeutic's drug has the same mechanis
Post# of 148186
Quote:
The use of glucagon-like peptide-1 (GLP-1) receptor agonists for diabetes and weight loss management – including semaglutide (Ozempic/Rybelsus/Wegovy, Novo Nordisk) – have previously been linked to adverse GI events such as abdominal pain, constipation, diarrhea, nausea and vomiting. Following post-marketing adverse reaction reports of patients who developed ileus while prescribed Ozempic, the FDA has opted to revise the drug label to alert prescribers of this potential risk.
https://www.healio.com/news/gastroenterology/...cemia-risk